Early Stage Innovation's Chance to Save Itself
Congressional pursuit of HR 9-type comprehensive patent reform seems to have slowed. Maybe inventors, investigators and investors can breathe easy for a while. Or not! Unless universities and others engaged in early stage commercialization can convince Congress now that Bayh-Dole-based commercialization is the bridge created by Congress to connect past and future congressional R&D funding to the public benefits of jobs, growth and medical progress contemplated by its annual R&D appropriation, trouble lies ahead.
R&D funding on one side of the commercialization bridge must reliably cross to its public benefit other side or Congress will invest its billions elsewhere. This bridge connects congressional investment with private sector investment and can fail on either side.
7701 Las Colinas Blvd., Ste. 800, Irving, TX 75063